Finasteride does not increase the risk of high-grade prostate cancer: A bias-adjusted modeling approach

Mary W. Redman, Catherine M. Tangen, Phyllis J. Goodman, M. Scott Lucia, Charles A. Coltman, Ian M. Thompson

Research output: Contribution to journalArticle

158 Citations (Scopus)

Abstract

Finasteride taken for 7 years in the Prostate Cancer Prevention Trial (PCPT) reduced the risk of prostate cancer by 25%, but with an apparent increased risk of high-grade disease. Subsequent analyses found that finasteride biases toward improved prostate cancer detection and accuracy in prostate cancer grading at biopsy. In our first analysis of the present study, we accounted for these biases in estimating the effect of finasteride on the risk of overall and high-grade prostate cancer. This analysis used PCPT data that included 3-month longer collection of endpoints than in the original report with observed prostate cancer rates of 22.9% (4.8% with high grade; placebo) versus 16.6% (5.8% with high grade; finasteride). Based on these updated results, the bias-adjusted prostate cancer rates are estimated to be 21.1% (4.2% high grade; placebo) and 14.7% (4.8% high grade; finasteride), a 30% risk reduction in prostate cancer [relative risk (RR), 0.70; 95% confidence interval (95% CI), 0.64-0.76; P < 0.0001] and a nonsignificant 14% increase in high-grade cancer (RR, 1.14; 95% CI, 0.96-1.35; P = 0.12) with finasteride. We then estimated rates of high-grade prostate cancer based on an analysis that incorporated grading information from radical prostatectomies in 500 subjects diagnosed with cancer. The resulting estimates were high-grade cancer rates of 8.2% (placebo) versus 6.0% (finasteride), a 27% risk reduction (RR, 0.73; 95% CI, 0.56-0.96; P = 0.02) with finasteride. Our third analysis examined the impact of biopsy sensitivity on the relative risk of high-grade prostate cancer and found that differential sensitivity of biopsy between the treatment arms can have a significant impact on risk ratio estimates. These collective results suggest that the observed, unadjusted higher risk of high-grade disease with finasteride seems to have been due to facilitated diagnosis resulting primarily from increased biopsy sensitivity with finasteride. Therefore, men undergoing regular prostate cancer screening or who express an interest in cancer prevention should be informed of the opportunity to take finasteride for preventing prostate cancer.

Original languageEnglish (US)
Pages (from-to)174-181
Number of pages8
JournalCancer Prevention Research
Volume1
Issue number3
DOIs
StatePublished - Aug 2008

Fingerprint

Finasteride
Prostatic Neoplasms
Biopsy
Placebos
Confidence Intervals
Risk Reduction Behavior
Neoplasms
Prostatectomy
Early Detection of Cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Redman, M. W., Tangen, C. M., Goodman, P. J., Lucia, M. S., Coltman, C. A., & Thompson, I. M. (2008). Finasteride does not increase the risk of high-grade prostate cancer: A bias-adjusted modeling approach. Cancer Prevention Research, 1(3), 174-181. https://doi.org/10.1158/1940-6207.CAPR-08-0092

Finasteride does not increase the risk of high-grade prostate cancer : A bias-adjusted modeling approach. / Redman, Mary W.; Tangen, Catherine M.; Goodman, Phyllis J.; Lucia, M. Scott; Coltman, Charles A.; Thompson, Ian M.

In: Cancer Prevention Research, Vol. 1, No. 3, 08.2008, p. 174-181.

Research output: Contribution to journalArticle

Redman, Mary W. ; Tangen, Catherine M. ; Goodman, Phyllis J. ; Lucia, M. Scott ; Coltman, Charles A. ; Thompson, Ian M. / Finasteride does not increase the risk of high-grade prostate cancer : A bias-adjusted modeling approach. In: Cancer Prevention Research. 2008 ; Vol. 1, No. 3. pp. 174-181.
@article{b80f0eb5413d4b5f90b954b951e5f64e,
title = "Finasteride does not increase the risk of high-grade prostate cancer: A bias-adjusted modeling approach",
abstract = "Finasteride taken for 7 years in the Prostate Cancer Prevention Trial (PCPT) reduced the risk of prostate cancer by 25{\%}, but with an apparent increased risk of high-grade disease. Subsequent analyses found that finasteride biases toward improved prostate cancer detection and accuracy in prostate cancer grading at biopsy. In our first analysis of the present study, we accounted for these biases in estimating the effect of finasteride on the risk of overall and high-grade prostate cancer. This analysis used PCPT data that included 3-month longer collection of endpoints than in the original report with observed prostate cancer rates of 22.9{\%} (4.8{\%} with high grade; placebo) versus 16.6{\%} (5.8{\%} with high grade; finasteride). Based on these updated results, the bias-adjusted prostate cancer rates are estimated to be 21.1{\%} (4.2{\%} high grade; placebo) and 14.7{\%} (4.8{\%} high grade; finasteride), a 30{\%} risk reduction in prostate cancer [relative risk (RR), 0.70; 95{\%} confidence interval (95{\%} CI), 0.64-0.76; P < 0.0001] and a nonsignificant 14{\%} increase in high-grade cancer (RR, 1.14; 95{\%} CI, 0.96-1.35; P = 0.12) with finasteride. We then estimated rates of high-grade prostate cancer based on an analysis that incorporated grading information from radical prostatectomies in 500 subjects diagnosed with cancer. The resulting estimates were high-grade cancer rates of 8.2{\%} (placebo) versus 6.0{\%} (finasteride), a 27{\%} risk reduction (RR, 0.73; 95{\%} CI, 0.56-0.96; P = 0.02) with finasteride. Our third analysis examined the impact of biopsy sensitivity on the relative risk of high-grade prostate cancer and found that differential sensitivity of biopsy between the treatment arms can have a significant impact on risk ratio estimates. These collective results suggest that the observed, unadjusted higher risk of high-grade disease with finasteride seems to have been due to facilitated diagnosis resulting primarily from increased biopsy sensitivity with finasteride. Therefore, men undergoing regular prostate cancer screening or who express an interest in cancer prevention should be informed of the opportunity to take finasteride for preventing prostate cancer.",
author = "Redman, {Mary W.} and Tangen, {Catherine M.} and Goodman, {Phyllis J.} and Lucia, {M. Scott} and Coltman, {Charles A.} and Thompson, {Ian M.}",
year = "2008",
month = "8",
doi = "10.1158/1940-6207.CAPR-08-0092",
language = "English (US)",
volume = "1",
pages = "174--181",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Finasteride does not increase the risk of high-grade prostate cancer

T2 - A bias-adjusted modeling approach

AU - Redman, Mary W.

AU - Tangen, Catherine M.

AU - Goodman, Phyllis J.

AU - Lucia, M. Scott

AU - Coltman, Charles A.

AU - Thompson, Ian M.

PY - 2008/8

Y1 - 2008/8

N2 - Finasteride taken for 7 years in the Prostate Cancer Prevention Trial (PCPT) reduced the risk of prostate cancer by 25%, but with an apparent increased risk of high-grade disease. Subsequent analyses found that finasteride biases toward improved prostate cancer detection and accuracy in prostate cancer grading at biopsy. In our first analysis of the present study, we accounted for these biases in estimating the effect of finasteride on the risk of overall and high-grade prostate cancer. This analysis used PCPT data that included 3-month longer collection of endpoints than in the original report with observed prostate cancer rates of 22.9% (4.8% with high grade; placebo) versus 16.6% (5.8% with high grade; finasteride). Based on these updated results, the bias-adjusted prostate cancer rates are estimated to be 21.1% (4.2% high grade; placebo) and 14.7% (4.8% high grade; finasteride), a 30% risk reduction in prostate cancer [relative risk (RR), 0.70; 95% confidence interval (95% CI), 0.64-0.76; P < 0.0001] and a nonsignificant 14% increase in high-grade cancer (RR, 1.14; 95% CI, 0.96-1.35; P = 0.12) with finasteride. We then estimated rates of high-grade prostate cancer based on an analysis that incorporated grading information from radical prostatectomies in 500 subjects diagnosed with cancer. The resulting estimates were high-grade cancer rates of 8.2% (placebo) versus 6.0% (finasteride), a 27% risk reduction (RR, 0.73; 95% CI, 0.56-0.96; P = 0.02) with finasteride. Our third analysis examined the impact of biopsy sensitivity on the relative risk of high-grade prostate cancer and found that differential sensitivity of biopsy between the treatment arms can have a significant impact on risk ratio estimates. These collective results suggest that the observed, unadjusted higher risk of high-grade disease with finasteride seems to have been due to facilitated diagnosis resulting primarily from increased biopsy sensitivity with finasteride. Therefore, men undergoing regular prostate cancer screening or who express an interest in cancer prevention should be informed of the opportunity to take finasteride for preventing prostate cancer.

AB - Finasteride taken for 7 years in the Prostate Cancer Prevention Trial (PCPT) reduced the risk of prostate cancer by 25%, but with an apparent increased risk of high-grade disease. Subsequent analyses found that finasteride biases toward improved prostate cancer detection and accuracy in prostate cancer grading at biopsy. In our first analysis of the present study, we accounted for these biases in estimating the effect of finasteride on the risk of overall and high-grade prostate cancer. This analysis used PCPT data that included 3-month longer collection of endpoints than in the original report with observed prostate cancer rates of 22.9% (4.8% with high grade; placebo) versus 16.6% (5.8% with high grade; finasteride). Based on these updated results, the bias-adjusted prostate cancer rates are estimated to be 21.1% (4.2% high grade; placebo) and 14.7% (4.8% high grade; finasteride), a 30% risk reduction in prostate cancer [relative risk (RR), 0.70; 95% confidence interval (95% CI), 0.64-0.76; P < 0.0001] and a nonsignificant 14% increase in high-grade cancer (RR, 1.14; 95% CI, 0.96-1.35; P = 0.12) with finasteride. We then estimated rates of high-grade prostate cancer based on an analysis that incorporated grading information from radical prostatectomies in 500 subjects diagnosed with cancer. The resulting estimates were high-grade cancer rates of 8.2% (placebo) versus 6.0% (finasteride), a 27% risk reduction (RR, 0.73; 95% CI, 0.56-0.96; P = 0.02) with finasteride. Our third analysis examined the impact of biopsy sensitivity on the relative risk of high-grade prostate cancer and found that differential sensitivity of biopsy between the treatment arms can have a significant impact on risk ratio estimates. These collective results suggest that the observed, unadjusted higher risk of high-grade disease with finasteride seems to have been due to facilitated diagnosis resulting primarily from increased biopsy sensitivity with finasteride. Therefore, men undergoing regular prostate cancer screening or who express an interest in cancer prevention should be informed of the opportunity to take finasteride for preventing prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=61749092731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61749092731&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-08-0092

DO - 10.1158/1940-6207.CAPR-08-0092

M3 - Article

C2 - 19138953

AN - SCOPUS:61749092731

VL - 1

SP - 174

EP - 181

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 3

ER -